RU2527068C2 - Фармакодинамические маркеры, индуцированные интерфероном альфа - Google Patents

Фармакодинамические маркеры, индуцированные интерфероном альфа Download PDF

Info

Publication number
RU2527068C2
RU2527068C2 RU2009125616/10A RU2009125616A RU2527068C2 RU 2527068 C2 RU2527068 C2 RU 2527068C2 RU 2009125616/10 A RU2009125616/10 A RU 2009125616/10A RU 2009125616 A RU2009125616 A RU 2009125616A RU 2527068 C2 RU2527068 C2 RU 2527068C2
Authority
RU
Russia
Prior art keywords
ifnα
ifi6
isg15
ifi44l
ifit1
Prior art date
Application number
RU2009125616/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2009125616A (ru
Inventor
ЯО Ихон
ДЖАЛЛАЛ Бахиджа
ЧИБОТТИ Рикардо
КОЙЛ Антони
КИНЕР Питер
Original Assignee
Медиммун, Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиммун, Ллк filed Critical Медиммун, Ллк
Publication of RU2009125616A publication Critical patent/RU2009125616A/ru
Application granted granted Critical
Publication of RU2527068C2 publication Critical patent/RU2527068C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
RU2009125616/10A 2006-12-06 2007-12-06 Фармакодинамические маркеры, индуцированные интерфероном альфа RU2527068C2 (ru)

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
US87300806P 2006-12-06 2006-12-06
US60/873,008 2006-12-06
US90776707P 2007-04-16 2007-04-16
US90776207P 2007-04-16 2007-04-16
US60/907,767 2007-04-16
US60/907,762 2007-04-16
US92421907P 2007-05-03 2007-05-03
US92422007P 2007-05-03 2007-05-03
US60/924,220 2007-05-03
US60/924,219 2007-05-03
US92458407P 2007-05-21 2007-05-21
US60/924,584 2007-05-21
US96018707P 2007-09-19 2007-09-19
US60/960,187 2007-09-19
US99617607P 2007-11-05 2007-11-05
US99617407P 2007-11-05 2007-11-05
US60/996,176 2007-11-05
US60/996,174 2007-11-05
US99621907P 2007-11-06 2007-11-06
US60/996,219 2007-11-06
US99682007P 2007-12-06 2007-12-06
US60/996,820 2007-12-06
PCT/US2007/024941 WO2008070135A2 (en) 2006-12-06 2007-12-06 Methods of treating systemic lupus erythematosus
USPCT/US2007/024941 2007-12-06
PCT/US2007/024947 WO2008070137A2 (en) 2006-12-06 2007-12-06 Interferon alpha-induced pharmacodynamic markers
US51733310A 2010-02-17 2010-02-17
US14/330,609 US20150044222A1 (en) 2006-12-06 2014-07-14 Interferon alpha-induced pharmacodynamic markers and uses thereof

Publications (2)

Publication Number Publication Date
RU2009125616A RU2009125616A (ru) 2011-07-27
RU2527068C2 true RU2527068C2 (ru) 2014-08-27

Family

ID=39492862

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2009125616/10A RU2527068C2 (ru) 2006-12-06 2007-12-06 Фармакодинамические маркеры, индуцированные интерфероном альфа
RU2014127178A RU2014127178A (ru) 2006-12-06 2014-07-03 Фармакодинамические маркеры, индуцированные интерфероном альфа2009125616 06.12.2006

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2014127178A RU2014127178A (ru) 2006-12-06 2014-07-03 Фармакодинамические маркеры, индуцированные интерфероном альфа2009125616 06.12.2006

Country Status (10)

Country Link
US (5) US20100143373A1 (https=)
EP (3) EP2077858A4 (https=)
JP (4) JP2010512315A (https=)
KR (2) KR20090088932A (https=)
AU (2) AU2007327993B2 (https=)
BR (2) BRPI0720035A2 (https=)
CA (2) CA2670594A1 (https=)
MX (1) MX2009005787A (https=)
RU (2) RU2527068C2 (https=)
WO (2) WO2008070135A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112464A1 (en) * 2016-12-16 2018-06-21 The Penn State Research Foundation Methods for improved reproductive management of ruminant ungulates
RU2811690C1 (ru) * 2022-12-28 2024-01-17 федеральное государственное автономное образовательное учреждение высшего образования "Санкт-Петербургский политехнический университет Петра Великого" (ФГАОУ ВО "СПбПУ") Тест-система для количественной диагностики мРНК генов MxA, OAS1, EIF2AK2 человека на основе ПЦР

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2077858A4 (en) * 2006-12-06 2011-07-20 Medimmune Llc INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
EP2076590A4 (en) * 2007-05-03 2011-06-01 Medimmune Llc SELF-IMMUNE DISEASE SELF-ANTIBODY MARKERS
ES2542836T3 (es) * 2007-07-12 2015-08-12 The Brigham And Women's Hospital, Inc. Composiciones y métodos para diagnosticar y evaluar miopatías inflamatorias
PT2219452E (pt) 2007-11-05 2016-01-26 Medimmune Llc Métodos de tratamento de esclerodermia
SG188147A1 (en) * 2008-02-08 2013-03-28 Medimmune Llc Disease markers and uses thereof
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
US20120251546A1 (en) * 2009-09-03 2012-10-04 Medimmune Llc Type 1 inteferon diagnostic
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US9709565B2 (en) 2010-04-21 2017-07-18 Memed Diagnostics Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
US20130317040A1 (en) * 2010-12-22 2013-11-28 The Feinstein Institute Of Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors
AU2012249601A1 (en) * 2011-04-26 2013-05-09 Genentech, Inc. Compositions and method for treating autoimmune diseases
AU2013204880B2 (en) * 2011-04-26 2016-11-24 Genentech, Inc. Compositions and method for treating autoimmune diseases
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
EP3367099B1 (en) 2012-02-09 2021-05-26 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
US20150168398A1 (en) 2012-05-17 2015-06-18 The Johns Hopkins University Methods for identifying patterns of ifn induced expression and use in diagnosis, monitoring and therapy
AU2013274389A1 (en) * 2012-06-13 2015-01-22 Astrazeneca Ab Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
US20140156297A1 (en) * 2012-08-03 2014-06-05 Axelacare Holdings, Inc. Computer program, method, and system for pharmacist-assisted treatment of patients
US20140039907A1 (en) * 2012-08-03 2014-02-06 AxelaCare Health Solutions, Inc. Computer program, method, and system for collecting patient data with a portable electronic device
US20140275257A1 (en) * 2013-03-14 2014-09-18 Foundation for the State University of New York N-acetyl cysteine compositions in the treatment of systemic lupus erythematosus
BR112017002884A2 (pt) 2014-08-14 2018-01-30 Memed Diagnostics Ltd ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano?
CN105420347A (zh) * 2014-08-21 2016-03-23 南京大学医学院附属鼓楼医院 一种用于系统性红斑狼疮的基因诊断试剂盒
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
CN111624345A (zh) 2014-12-11 2020-09-04 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
IL287757B (en) 2016-03-03 2022-07-01 Memed Diagnostics Ltd Analyzing rna for diagnosing infection type
EP3423590A4 (en) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. DETERMINANTS OF RNA TO DIFFERENTIATE BACTERIAL VIRAL INFECTIONS
EP3482201B1 (en) 2016-07-10 2022-12-14 Memed Diagnostics Ltd. Early diagnosis of infections
EP3482200B1 (en) 2016-07-10 2022-05-04 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
WO2018136625A2 (en) * 2017-01-20 2018-07-26 Children's Medical Center Corporation Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
US11926664B2 (en) 2017-07-25 2024-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EA202191133A1 (ru) * 2018-10-26 2021-07-12 Янссен Байотек, Инк. Сигнатуры интерферона типа i и способы их применения
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
EP3924383A1 (en) 2019-02-15 2021-12-22 Astrazeneca AB Type i interferon-mediated disorders
US12011284B2 (en) * 2020-05-19 2024-06-18 Peachy Corp. Systems and methods for preventing and treating wrinkles
KR102429261B1 (ko) 2020-08-25 2022-08-03 충북대학교 산학협력단 한국인의 tnf 저해제 약물 반응성 예측을 위한 바이오마커
AR123650A1 (es) * 2020-10-02 2022-12-28 Celgene Corp Métodos para el tratamiento del lupus eritematoso sistémico y el uso de biomarcadores como un predictor de sensibilidad clínica a terapias
HRP20231255T1 (hr) 2021-04-23 2024-02-02 Astrazeneca Ab Režim doziranja anti-ifnar1 za potkožnu injekciju
KR20240023602A (ko) 2021-06-18 2024-02-22 아이오니스 파마수티컬즈, 인코포레이티드 Ifnar1 발현을 감소시키기 위한 화합물 및 방법
FR3138815A1 (fr) * 2022-08-12 2024-02-16 bioMérieux Détermination de la nature virale ou bactérienne d’une infection
CN117305441B (zh) * 2023-10-13 2025-04-08 福建农林大学 一种2型糖尿病的生物标志物和治疗靶点及浒苔寡糖的应用方法
WO2025213238A1 (en) * 2024-04-12 2025-10-16 HaemaLogiX Ltd Anti-kma antibody formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2223115C2 (ru) * 1998-09-30 2004-02-10 Санкио Компани Лимитед ГУМАНИЗИРОВАННАЯ АНТИ-Fas АНТИТЕЛОПОДОБНАЯ МОЛЕКУЛА (ВАРИАНТЫ), ДНК (ВАРИАНТЫ), ВЕКТОР (ВАРИАНТЫ), ПОЛИПЕПТИД, СПОСОБ ПОЛУЧЕНИЯ, ИСПОЛЬЗОВАНИЕ АНТИТЕЛА
US20060177814A1 (en) * 2004-10-13 2006-08-10 Behrens Timothy W Systemic lupus erythematosus

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139676B1 (en) 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
FR2692168B1 (fr) 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
JP4285766B2 (ja) 1994-03-23 2009-06-24 オハイオ ユニバーシティ 緻密にした核酸および細胞へのデリバリ
US6905587B2 (en) * 1996-03-22 2005-06-14 Ronald Redline Method for enhancing the solderability of a surface
AU749032B2 (en) 1997-06-13 2002-06-20 Johns Hopkins University, The Therapeutic nanospheres
US20050008683A1 (en) * 2000-06-29 2005-01-13 Becton Dickinson And Company Method for delivering interferons to the intradermal compartment
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003046008A1 (en) * 2001-11-30 2003-06-05 Innogenetics N.V. Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma
EP2298360A3 (en) * 2002-11-21 2011-07-13 Bayhill Therapeutics, Inc. Methods and immune modulatory nucleic acid compositions for preventing and treating disease
CN1871252A (zh) * 2003-09-05 2006-11-29 Gtc生物治疗学公司 在转基因哺乳动物奶中生产融合蛋白的方法
NZ547157A (en) * 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
HUE035082T2 (en) * 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
US20070166281A1 (en) * 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
US7833795B2 (en) * 2004-08-24 2010-11-16 The Trustees Of The University Of Pennsylvania Assessment of cardiovascular risk using isoprostane biomarkers and COX-2 selective inhibitors
WO2006086586A2 (en) * 2005-02-10 2006-08-17 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US20070117105A1 (en) * 2005-05-12 2007-05-24 Crow Mary K Interferon assay
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
PT2327792E (pt) * 2005-08-05 2013-11-21 Genentech Inc Métodos e composições para a detecção de distúrbios autoimunes
US7608395B2 (en) * 2005-09-15 2009-10-27 Baylor Research Institute Systemic lupus erythematosus diagnostic assay
EA015860B1 (ru) * 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
EP2057190A4 (en) * 2006-08-09 2010-07-28 Baylor Res Inst MONOCLONAL ANTI-INTERFERON ALPHA ANTIBODIES AND USE METHOD THEREFOR
EP2077858A4 (en) * 2006-12-06 2011-07-20 Medimmune Llc INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
US20120251546A1 (en) * 2009-09-03 2012-10-04 Medimmune Llc Type 1 inteferon diagnostic

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2223115C2 (ru) * 1998-09-30 2004-02-10 Санкио Компани Лимитед ГУМАНИЗИРОВАННАЯ АНТИ-Fas АНТИТЕЛОПОДОБНАЯ МОЛЕКУЛА (ВАРИАНТЫ), ДНК (ВАРИАНТЫ), ВЕКТОР (ВАРИАНТЫ), ПОЛИПЕПТИД, СПОСОБ ПОЛУЧЕНИЯ, ИСПОЛЬЗОВАНИЕ АНТИТЕЛА
US20060177814A1 (en) * 2004-10-13 2006-08-10 Behrens Timothy W Systemic lupus erythematosus

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112464A1 (en) * 2016-12-16 2018-06-21 The Penn State Research Foundation Methods for improved reproductive management of ruminant ungulates
RU2815973C2 (ru) * 2019-02-15 2024-03-25 Астразенека Аб Нарушения, опосредованные интерфероном i типа
RU2811690C1 (ru) * 2022-12-28 2024-01-17 федеральное государственное автономное образовательное учреждение высшего образования "Санкт-Петербургский политехнический университет Петра Великого" (ФГАОУ ВО "СПбПУ") Тест-система для количественной диагностики мРНК генов MxA, OAS1, EIF2AK2 человека на основе ПЦР
RU2845958C1 (ru) * 2024-07-25 2025-08-28 Общество с ограниченной ответственностью "МайЛаборатори" Диагностическая тест-система для оценки функционального состояния системы интерферона при аутоиммунных воспалительных заболеваниях
RU2854593C1 (ru) * 2024-12-26 2026-01-14 Общество с ограниченной ответственностью "МайЛаборатори" Тест-система для определения уровня экспрессии генов интерфероновой сигнатуры при склеродермии

Also Published As

Publication number Publication date
US20100143373A1 (en) 2010-06-10
JP2010512313A (ja) 2010-04-22
AU2007327993B2 (en) 2013-06-20
RU2014127178A (ru) 2016-01-27
WO2008070137A3 (en) 2008-11-20
EP2073844A4 (en) 2011-06-01
CA2670594A1 (en) 2008-06-12
WO2008070135A2 (en) 2008-06-12
US20150147336A1 (en) 2015-05-28
AU2007327995B2 (en) 2013-10-10
KR20090088932A (ko) 2009-08-20
JP2014014370A (ja) 2014-01-30
AU2007327995A1 (en) 2008-06-12
US20100143372A1 (en) 2010-06-10
EP2712930A2 (en) 2014-04-02
BRPI0719912A2 (pt) 2014-03-04
KR101532797B1 (ko) 2015-07-01
EP2077858A2 (en) 2009-07-15
WO2008070137A2 (en) 2008-06-12
RU2009125616A (ru) 2011-07-27
BRPI0720035A2 (pt) 2019-05-07
MX2009005787A (es) 2009-06-08
CA2670897A1 (en) 2008-06-12
EP2077858A4 (en) 2011-07-20
JP2010512315A (ja) 2010-04-22
AU2007327993A1 (en) 2008-06-12
WO2008070135A8 (en) 2009-12-17
KR20090088931A (ko) 2009-08-20
WO2008070135A3 (en) 2008-11-27
EP2712930A3 (en) 2014-04-23
EP2073844A2 (en) 2009-07-01
US20150044222A1 (en) 2015-02-12
US20170121771A1 (en) 2017-05-04
JP2014040430A (ja) 2014-03-06

Similar Documents

Publication Publication Date Title
RU2527068C2 (ru) Фармакодинамические маркеры, индуцированные интерфероном альфа
AU2008247398B2 (en) Interferon alpha-induced pharmacodynamic markers
AU2010289383B2 (en) Type 1 interferon diagnostic
CN101999001B (zh) 疾病标志物及其用途
US20130142809A1 (en) METHODS OF TREATMENT USING AN IFN gamma INHIBITOR
US20110287022A1 (en) Interferon alpha-induced pharmacodynamic markers
CN101594882A (zh) 干扰素α诱导的药代动力学标记物
US20100261172A1 (en) Interferon alpha-induced pharmacodynamic markers
WO2009155559A1 (en) Interferon alpha-induced pharmacodynamic markers
AU2014200127A1 (en) Interferon alpha-induced pharmacodynamic markers
AU2014200128A1 (en) Interferon alpha-induced pharmacodynamic markers
HK1140406A (en) Interferon alpha-induced pharmacodynamic markers
AU2015203772A1 (en) Disease markers and uses thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20151207